The addition of Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel as a first-line therapy for metastatic HER2-positive breast cancer improved overall survival (OS) by nearly 16 months, according to findings from the phase 3 CLEOPATRA study.
One of the greatest challenges facing potential Lynch syndrome carriers is not having advice on the implications of a pending test and a subsequent positive result.
What does it take for patients with cancer who have exhausted their other medical options to gain access to late-stage investigational drugs?
Experts offer tips for patients and survivors to overcome feelings of guilt.
The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor Zelboraf to treat patients with BRAF V600–positive advanced melanoma.
When a 15-year old girl tells us that her concerns need to be heard by her doctors and other medical practitioners, we all need to listen.
A simple guide can help patients understand immunotherapies for cancer.
The FDA has approved Revlimid plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase 3 FIRST trial.
Staying alive is most people's top priority and oncologists have more and more tools and tactics for keeping patients alive. Yet beyond keeping us alive, there is so much more.
The weeks and days leading up to transplant, the anticipation and reality
There are various avenues caregivers can use to reach out for online social support and cancer-related information.
Melanoma rates are on the rise, and is the most common form of cancer for young adults aged 25 to 29 years old.
As a comedic actress, Julia Sweeney can usually find the humor in just about any situation, but when diagnosed with cervical cancer, she felt more of a punch than a punchline. Learning that humor was her way of healing came soon afterward, though.
Not every cancer patient seeks, needs or wants a second opinion.
Talk with almost any cancer survivor, and he or she is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory. A review of the research shows how we're focusing on the problem.
ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer patients with localized disease to receive high quality care from specialists and primary care physicians.
Scan anxiety haunts virtually every person dealing with cancer. Here are a few tips for managing the stress.
This Valentine's Day is extra special as our hearts are brimmed with happiness and our lives are filled with love. I recognize the courage and beauty it takes to live with cancer together.
Intimacy after a cancer diagnosis can be difficult due to emotional and physical side effects, but it can also be an important part of healing.
Information and advice about bone marrow transplants from the man who owns one
I went into dating after cancer with one goal, a decent date, and I got far more than I ever dreamed.
The FDA has granted approval to Lenvima (lenvatinib) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase 3 SELECT trial.
It's isolating to have cancer. Making a connection with someone who understands makes all the difference.
Richard Finn, of the Jonsson Comprehensive Cancer Center at UCLA and lead investigator of the PALOMA-1 study, explains the clinical implications of Ibrance's approval for hormone-positive, HER2-negative metastatic breast cancer.
With a deadline of April 14, the FDA will soon make its final approval decision on lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.
Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.
The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.
At least 10 vaccine candidates have entered advanced testing phases on the strength of impressive early stage results.
Medicare will immediately cover lung cancer screening with low-dose computed tomography (LDCT) for high-risk individuals, including current and former smokers, according to a national coverage determination (NCD) released by CMS.
